{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:57:08Z","timestamp":1790510228388,"version":"4.1.0"},"reference-count":48,"publisher":"JLE","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.nephro.2018.02.009","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T15:30:56Z","timestamp":1522337456000},"page":"S133-S138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S1","title":["N\u00e9phrotoxicit\u00e9 de la vancomycine\u00a0: fr\u00e9quence et m\u00e9canismes"],"prefix":"10.1684","volume":"14","author":[{"given":"Yosu","family":"Luque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mesnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","reference":[{"issue":"7","key":"10.1016\/j.nephro.2018.02.009_bib0245","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.294.7.813","article-title":"Acute renal failure in critically ill patients: a multinational, multicenter study","volume":"294","author":"Uchino","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.nephro.2018.02.009_bib0250","doi-asserted-by":"crossref","first-page":"844","DOI":"10.2215\/CJN.05191107","article-title":"Diagnosis, epidemiology and outcomes of acute kidney injury","volume":"3","author":"Waikar","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl. 1","key":"10.1016\/j.nephro.2018.02.009_bib0255","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/491709","article-title":"Vancomycin: a history","volume":"42","author":"Levine","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nephro.2018.02.009_bib0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/14.suppl_D.1","article-title":"Vancomycin use\u00a0\u2013\u00a0an historical review","volume":"14\u00a0Suppl. D","author":"Griffith","year":"1984","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.nephro.2018.02.009_bib0265","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2215\/CJN.11011016","article-title":"Vancomycin and the risk of AKI: now clearer than Mississippi Mud","volume":"0711","author":"Nolin","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8638","key":"10.1016\/j.nephro.2018.02.009_bib0270","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0140-6736(89)91664-4","article-title":"Vancomycin and nephrotoxicity","volume":"1","author":"Gudmundsson","year":"1989","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.nephro.2018.02.009_bib0275","first-page":"379","article-title":"Vancomycin nephrotoxicity: myths and facts","volume":"69","author":"Gupta","year":"2011","journal-title":"Neth J Med"},{"issue":"3","key":"10.1016\/j.nephro.2018.02.009_bib0280","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.nephro.2018.02.009_bib0285","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1128\/AAC.23.1.138","article-title":"Retrospective study of the toxicity of preparations of vancomycin from 1974\u00a0to 1981","volume":"23","author":"Farber","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.009_bib0290","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/jac\/15.6.773","article-title":"Vancomycin toxicity: a prospective study","volume":"15","author":"Mellor","year":"1985","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.nephro.2018.02.009_bib0295","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1128\/AAC.19.2.306","article-title":"Effects of vancomycin on renal function in rats","volume":"19","author":"Aronoff","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.nephro.2018.02.009_bib0300","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1128\/AAC.30.1.20","article-title":"Vancomycin enhancement of experimental tobramycin nephrotoxicity","volume":"30","author":"Wood","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nephro.2018.02.009_bib0305","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1093\/clinids\/3.Supplement_2.S224","article-title":"Toxicology of vancomycin in laboratory animals","volume":"3\u00a0Suppl.","author":"Wold","year":"1981","journal-title":"Rev Infect Dis"},{"issue":"3","key":"10.1016\/j.nephro.2018.02.009_bib0310","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jac\/14.3.253","article-title":"Renal tolerance and pharmacokinetics of vancomycin in rats","volume":"14","author":"Marre","year":"1984","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.009_bib0315","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1681\/ASN.2016080867","article-title":"Vancomycin-associated cast nephropathy","volume":"28","author":"Luque","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.nephro.2018.02.009_bib0320","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.nephro.2018.02.009_bib0325","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.nephro.2018.02.009_bib0330","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/j.1875-9114.1995.tb04335.x","article-title":"Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia","volume":"15","author":"Zimmermann","year":"1995","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.nephro.2018.02.009_bib0335","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/jac\/25.4.679","article-title":"Nephrotoxicity of vancomycin, alone and with an aminoglycoside","volume":"25","author":"Rybak","year":"1990","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.nephro.2018.02.009_bib0340","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-198611040-00001","article-title":"Clinical pharmacokinetics of vancomycin","volume":"11","author":"Matzke","year":"1986","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.009_bib0345","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/AAC.20.6.718","article-title":"Comparison of vancomycin disposition in rats with normal and abnormal renal functions","volume":"20","author":"Engineer","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"issue":"19","key":"10.1016\/j.nephro.2018.02.009_bib0350","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.nephro.2018.02.009_bib0355","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1517\/14740330903413514","article-title":"Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections","volume":"9","author":"Hermsen","year":"2010","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"10.1016\/j.nephro.2018.02.009_bib0360","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-017-0764-7","article-title":"The whole price of vancomycin: toxicities, troughs, and time","volume":"77","author":"Jeffres","year":"2017","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.009_bib0365","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","article-title":"A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia","volume":"29","author":"Jeffres","year":"2007","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.009_bib0370","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ijantimicag.2009.07.011","article-title":"Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy","volume":"34","author":"Ingram","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.nephro.2018.02.009_bib0375","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/ALN.0b013e3181a97272","article-title":"Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion","volume":"111","author":"Hutschala","year":"2009","journal-title":"Anesthesiology"},{"issue":"4","key":"10.1016\/j.nephro.2018.02.009_bib0380","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2710.2004.00572.x","article-title":"High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion","volume":"29","author":"Vuagnat","year":"2004","journal-title":"J Clin Pharm Ther"},{"issue":"20","key":"10.1016\/j.nephro.2018.02.009_bib0385","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJM198005153022002","article-title":"Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin","volume":"302","author":"Smith","year":"1980","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.nephro.2018.02.009_bib0390","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1128\/AAC.34.1.139","article-title":"Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats","volume":"34","author":"Beauchamp","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.nephro.2018.02.009_bib0395","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jpeds.2010.08.019","article-title":"Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children","volume":"158","author":"McKamy","year":"2011","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.009_bib0400","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jiph.2016.11.007","article-title":"Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or with meropenem","volume":"10","author":"Al Yami","year":"2017","journal-title":"J Infect Public Health"},{"issue":"7","key":"10.1016\/j.nephro.2018.02.009_bib0405","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/phar.1442","article-title":"Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam","volume":"34","author":"Burgess","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.nephro.2018.02.009_bib0410","doi-asserted-by":"crossref","first-page":"e173219","DOI":"10.1001\/jamapediatrics.2017.3219","article-title":"Association of acute kidney injury with concomitant vancomycin and piperacillin\/tazobactam treatment among hospitalized children","volume":"171","author":"Downes","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"5","key":"10.1016\/j.nephro.2018.02.009_bib0415","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciw811","article-title":"Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin\/tazobactam","volume":"64","author":"Hammond","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.nephro.2018.02.009_bib0420","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1097\/PCC.0000000000001335","article-title":"Increased risk of acute kidney injury in critically ill children treated with vancomycin and piperacillin\/tazobactam","volume":"18","author":"Holsen","year":"2017","journal-title":"Pediatr Crit Care Med"},{"issue":"3","key":"10.1016\/j.nephro.2018.02.009_bib0425","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/phar.1901","article-title":"Comparison of rates of nephrotoxicity associated with vancomycin in combination with piperacillin-tazobactam administered as an extended versus standard infusion","volume":"37","author":"Mousavi","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.nephro.2018.02.009_bib0430","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.2042-7158.1996.tb03920.x","article-title":"In-vivo clearance study of vancomycin in rats","volume":"48","author":"Nakamura","year":"1996","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.nephro.2018.02.009_bib0435","doi-asserted-by":"crossref","first-page":"436856","DOI":"10.4061\/2011\/436856","article-title":"Biopsy-proven acute tubular necrosis due to vancomycin toxicity","volume":"2011","author":"Shah-Khan","year":"2011","journal-title":"Int J Nephrol"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.009_bib0440","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0272-6386(89)80152-0","article-title":"Tubulointerstitial nephritis due to vancomycin","volume":"14","author":"Codding","year":"1989","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.nephro.2018.02.009_bib0445","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/toxsci\/kfn203","article-title":"Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates","volume":"107","author":"Dieterich","year":"2009","journal-title":"Toxicol Sci"},{"issue":"5","key":"10.1016\/j.nephro.2018.02.009_bib0450","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1179\/joc.2001.13.5.461","article-title":"Renal transport of antibiotics and nephrotoxicity: a review","volume":"13","author":"Fanos","year":"2001","journal-title":"J Chemother"},{"issue":"4","key":"10.1016\/j.nephro.2018.02.009_bib0455","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/1071576031000061002","article-title":"Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats","volume":"37","author":"Nishino","year":"2003","journal-title":"Free Radic Res"},{"issue":"3","key":"10.1016\/j.nephro.2018.02.009_bib0460","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.tox.2005.07.009","article-title":"In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine","volume":"215","author":"Oktem","year":"2005","journal-title":"Toxicology"},{"issue":"11","key":"10.1016\/j.nephro.2018.02.009_bib0465","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/j.1440-1681.2007.04695.x","article-title":"Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model","volume":"34","author":"Cetin","year":"2007","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.nephro.2018.02.009_bib0470","first-page":"1","article-title":"Effect of pycnogenol and spirulina on vancomycin-induced renal cortical oxidative stress, apoptosis, and autophagy in adult male albino rat","volume":"6","author":"Bayomy","year":"2016","journal-title":"Can J Physiol Pharmacol"},{"issue":"4","key":"10.1016\/j.nephro.2018.02.009_bib0475","doi-asserted-by":"crossref","first-page":"e0152554","DOI":"10.1371\/journal.pone.0152554","article-title":"Exposure to hyperbaric oxygen intensified vancomycin-induced nephrotoxicity in rats","volume":"11","author":"Sabler","year":"2016","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.009_bib0240","doi-asserted-by":"crossref","first-page":"e0127791","DOI":"10.1371\/journal.pone.0127791","article-title":"Genome-Wide Association Study of serum creatinine levels during vancomycin therapy","volume":"10","author":"Van Driest","year":"2015","journal-title":"PloS One"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725518300245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725518300245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2018.02.009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T02:47:35Z","timestamp":1751510855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725518300245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":48,"alternative-id":["S1769725518300245"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2018.02.009","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N\u00e9phrotoxicit\u00e9 de la vancomycine\u00a0: fr\u00e9quence et m\u00e9canismes","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2018.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}